{"id":259,"date":"2020-06-06T15:57:00","date_gmt":"2020-06-06T15:57:00","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=259"},"modified":"2020-06-06T15:57:00","modified_gmt":"2020-06-06T15:57:00","slug":"05-june-2020-tocilizumab-less-icu-admissions-10-3-vs-27-6-p-0-005-in-tocilizumab-group","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/05-june-2020-tocilizumab-less-icu-admissions-10-3-vs-27-6-p-0-005-in-tocilizumab-group\/","title":{"rendered":"(05 June 2020) Tocilizumab- less ICU admissions (10.3% vs. 27.6%, P= 0.005) in Tocilizumab group"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1101\/2020.06.05.20113738<\/p>\n<p class=\"\">In a retrospective study ,77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0\u22191, P=0.0001) of ICU admission or death. Tocilizumab in the early stages of the inflammatory flare, could reduce ICU admissions and mechanical ventilation use. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection https:\/\/doi.org\/10.1101\/2020.06.05.20113738 In a retrospective study ,77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P=&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/05-june-2020-tocilizumab-less-icu-admissions-10-3-vs-27-6-p-0-005-in-tocilizumab-group\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(05 June 2020) Tocilizumab- less ICU admissions (10.3% vs. 27.6%, P= 0.005) in Tocilizumab group&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/259"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=259"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/259\/revisions"}],"predecessor-version":[{"id":261,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/259\/revisions\/261"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}